Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA18 in RAS-altered solid tumors
NCT05012618Phase 1Terminated
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of paluratide in solid tumor (6 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 6 more. Started Oct 2021; status: terminated.
02
Drugs
paluratide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05012618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012618.